Breaking News, Financial News

2Q Financial Report: Johnson & Johnson

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Johnson & Johnson   2Q Revenues: $13.4 billion (+5%) 2Q Earnings: $2.8 billion (+7%) YTD Revenues: $26.4 billion (+3%) YTD Earnings: $6.1 billion (+13%) Comments: Worldwide pharmaceutical sales were $5.8 billion for the quarter, up 3.2%. Sales growth for the quarter was driven by Risperdal, Remicade, Topamax, and Concerta. During the quarter, the FDA approved Ionsys, the first needle-free, patient-activated analgesic system and Remicade for reducing signs and symptoms in p...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters